Skye Bioscience, Inc. financial data

Symbol
SKYE on Nasdaq
Location
San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 852 % +54.9%
Debt-to-equity 13.3 % -40.3%
Return On Equity -100 % -167%
Return On Assets -88.7 % -188%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.1M shares +5.67%
Common Stock, Shares, Outstanding 31M shares +2.15%
Entity Public Float 225M USD +1002%
Common Stock, Value, Issued 31K USD +2.15%
Weighted Average Number of Shares Outstanding, Basic 39.7M shares +2.18%
Weighted Average Number of Shares Outstanding, Diluted 39.7M shares +2.18%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.29M USD +52.2%
General and Administrative Expense 16.9M USD +8.07%
Operating Income (Loss) -53.9M USD -128%
Nonoperating Income (Expense) 2.71M USD +13.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -51.2M USD -141%
Income Tax Expense (Benefit) 5.4K USD -46.4%
Net Income (Loss) Attributable to Parent -51.2M USD -141%
Earnings Per Share, Basic -1 USD/shares -153%
Earnings Per Share, Diluted -1 USD/shares -153%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 18.4M USD -72.6%
Cash, Cash Equivalents, and Short-term Investments 35.3M USD
Other Assets, Current 900K USD -66%
Assets, Current 39.9M USD -50%
Property, Plant and Equipment, Net 1.03M USD -31.8%
Operating Lease, Right-of-Use Asset 312K USD +68.9%
Other Assets, Noncurrent 53.9K USD +105%
Assets 41.3M USD -49.3%
Accounts Payable, Current 2.83M USD +262%
Employee-related Liabilities, Current 921K USD +1.94%
Liabilities, Current 8.37M USD +48.8%
Operating Lease, Liability, Noncurrent 120K USD +11.2%
Liabilities 8.49M USD +48.1%
Retained Earnings (Accumulated Deficit) -172M USD -42.3%
Stockholders' Equity Attributable to Parent 32.8M USD -56.7%
Liabilities and Equity 41.3M USD -49.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.19M USD -95.1%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -12.8M USD -1222%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 31M shares +2.15%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -22M USD -127%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.4M USD -75.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 126K USD +2848%
Deferred Tax Assets, Valuation Allowance 67.7M USD +1.93%
Deferred Tax Assets, Gross 67.8M USD +1.99%
Operating Lease, Liability 456K USD +87.3%
Depreciation 27.6K USD -16.9%
Payments to Acquire Property, Plant, and Equipment 6.31K USD +98.4%
Lessee, Operating Lease, Liability, to be Paid 504K USD +67.8%
Property, Plant and Equipment, Gross 1.67M USD +1101%
Operating Lease, Liability, Current 202K USD +143%
Lessee, Operating Lease, Liability, to be Paid, Year Two 203K USD +90.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 215K USD +108%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure -26.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 48.3K USD -15.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 85.9K USD -5.36%
Deferred Tax Assets, Operating Loss Carryforwards 41.6M USD +1.78%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200K shares 0%
Unrecognized Tax Benefits 9.5M USD +47.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 177K USD +544%
Deferred Tax Assets, Net of Valuation Allowance 94.5K USD +89%
Share-based Payment Arrangement, Expense 8.24M USD +20.8%
Interest Expense 1.32M USD +173%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%